INFECTIOUS COMPLICATIONS CAUSED BY NON-SPOREFORMING ANAEROBIC BACTERIA IN CANCER PATIENTS. RELEVANCE OF THE PROBLEM

The purpose of the study: to identify the significance of anaerobic bacteria and analyze their role in the development of infectious complications in cancer patients.
Material and Methods. The review includes data from clinical and in vitro studies published in Russian and international press for the period from 1989 to 2018.
Results. Data analysis has shown that many aspects related to anaerobic non-sporeforming bacteria are insufficiently studied, although they can cause severe hospital infections. This is especially true for patients with immune system defects, including cancer patients. In this category of patients, anaerobic bacteria can cause infections of the maxillofacial region, intra-abdominal infections, lower respiratory tract infections, urinary infections, and blood flow infections. In cancer patients, infectious complications are more severe, and may adversely affect treatment outcomes. A long process of anaerobic cultivation dictates the need for empirical treatment of infection for an average of 6 to 7 days. Since the middle of the last century, metronidazole was the «gold standard» of therapy. However, today the situation has changed dramatically. More than 80 % of anaerobic strains are resistant to metronidazole. The problem of resistance of anaerobic bacteria to other antibacterial drugs has not been sufficiently studied.
Conclusion. It is necessary to develop therapeutic approaches based on current data on the resistance mechanisms of non-sporeforming anaerobic bacteria.

non-sporeforming anaerobic bacteria, cancer patients, metronidazole, clindamycin, protected penicillins, resistance, anti-anaerobic drugs

1. Zubkov M.N. Modern taxonomy and nomenclature of obligate-anaerobic bacteria isolated from humans. Clinical Microbiology and Antimicrobial Chemotherapy. Clinical Microbiology and Antimicrobial Chemotherapy 2005; 7(4): 312–314. (in Russian).

2. Finegold S.M., George W.L. Anaerobic infections in humans. NewYork: Academic Press. 1989. 851 p.

3. Davydov M.I., Dmitrieva N.V. Infections in oncology. Moscow, 2009.472 p. (in Russian).

4. Brooк I. Contemporary Diagnosis and Management of Anaerobic infections. Pennsylvania. Newtown: HHC. 2004. 268 p.

5. Grigorievskaya Z.V. Urgency of the problem of hospital infections in cancer patients. Journal of N.N. Blokhin Russian Cancer Research Center RAMS. 2013; 24 (3–4): 46–49. (in Russian).

6. Dewhirst F.E., Chen T., Izard J., Paster B.J., Tanner A.C., Yu W.H., Lakshmanan A., Wade W.G. The human oral microbiome. J Bacteriol. 2010 Oct; 192(19): 5002–17. doi: 10.1128/JB.00542-10.

7. Finegold S.M., Jousimies-Somer H. Recently described clinically important anaerobic bacteria: medical aspects. Clin Infect Dis. 1997 Sep; 25 Suppl 2: S88–93. doi: 10.1086/516237.

8. Jousimies-Somer H., Summanen P., Citron D., Baron E., Wexler H., Finegold S. Anaerobic Bacteriology Manual. Belmont, California: Star Publishing Company. 2002. 287 p.

9. Byung K., Geoffrey M. Bacterial Physiology and Metabolism. Cambridge: Cambridge University Press. 2008. 496–529 p.

10. Bowler P.G., Duerden B.I., Armstrong D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev. 2001 Apr; 14(2): 244–69. doi: 10.1128/CMR.14.2.244-269.2001.

11. Gelfond V.M. Infectious complications in cancer patients. Practical Oncology. 2009; 10(3): 141–146. (in Russian).

12. Greene J. Infections in cancer Patients. New York: Marcel Dekker. 2004. 534 р.

13. Shilnikova I.I., Dmitrieva N.V. Evaluation of antibiotic susceptibility of Bacteroides, Prevotella and Fusobacterium species isolated from cancer patients of the N.N. Blokhin Cancer Research Center, Moscow, Russia. Anaerobe. 2014; 31: 1–4. doi: 10.1016/j.anaerobe.2014.08.003.

14. Tereshchenko I.V., Grigorievskaya Z.V., Petukhova I.N., Shilnikova I.I., Grigorievsky Е.D., Tereshchenko О.V., Aginova V.V., Dmitrieva N.V. Role of gram-negative anaerobic cocci belonging to the genus Veillonella in infectious complications in cancer patients. Siberian Journal of Oncology. 2018; 17(1): 11–18. (in Russian). doi: 10.21294/1814-4861-2018-17-1-11-18.

15. Shah H.N., Olsen I., Bernard K., Finegold S.M., Gharbia S., Gupta R.S. Approaches to the study of the systematics of anaerobic, gramnegative, non-sporeforming rods: current status and perspectives. Anaerobe. 2009 Oct; 15(5): 179–94. doi: 10.1016/j.anaerobe.2009.08.003.

16. Barreau M., Pagnier I., La Scola B. Improving the identification of anaerobes in the clinical microbiology laboratory through MALDITOF mass spectrometry. Anaerobe. 2013; 22: 123–5. doi: 10.1016/j.anaerobe.2013.04.011.

17. Fedorko D.P., Drake S.K., Stock F., Murray P.R. Identification of clinical isolates of anaerobic bacteria using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Eur J Clin Microbiol Infect Dis. 2012 Sep; 31(9): 2257–62. doi: 10.1007/s10096-012-1563-4.

18. Fournier R., Wallet F., Grandbastien B., Dubreuil L., Courcol R., Neut C., Dessein R. Chemical extraction versus direct smear for MALDITOF mass spectrometry identification of anaerobic bacteria. Anaerobe. 2012 Jun; 18(3): 294–7. doi: 10.1016/j.anaerobe.2012.03.008.

19. Kostrzewa M., Schubert S. MALDI-TOF mass spectrometry in microbiology. Bremen: Caister Academic Press. 2016. 170 p.

20. Dmitrieva N.V., Petuhova I.N. Antimicrobial therapy for nosocomial infections. Moscow, 2014. 326 p. (in Russian).

21. Galkin D.V., Krechikova O.I., Suhorukova M.V., Dehnich A.V. Current state of anty-anaerobic therapy. Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4): 298–313. (in Russian).

22. Brooк I. Antibiotic Resistance of Anaerobic Bacteria. Antimicrobial drug resistance. Humana press. 2009. 873–899 p.

23. Dubreuil L., Odou M.F. Anaerobic bacteria and antibiotics: What kind of unexpected resistance could I find in my laboratory tomorrow? Anaerobe. 2010 Dec; 16(6): 555–9. doi: 10.1016/j.anaerobe.2010.10.002.

24. Alauzet C., Mory F., Teyssier C., Hallage H., Carlier J.P., Grollier G., Lozniewski A. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother. 2010 Jan; 54(1): 60–4. doi: 10.1128/AAC.01003-09.

25. Achermann Y., Goldstein E.J., Coenye T., Shirtliff M.E. Propionibacterium

26. acnes: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev. 2014 Jul; 27(3): 419–40. doi: 10.1128/CMR.00092-13.

27. Viswanath B.G., Lakshmi G.J., Nagamani K., Reddy N.V.N., Rao G.P., Srinivas S.S.S., Dashetwar A.M. Emergence of Antimicrobial Resistance among Anaerobic Bacteria. Am J Infect Dis Microbiol. 2017; 5(2): 87–93. doi: 10.12691/ajidm-5-2-3.

28. EUCAST Expert Rules [Internet]. URL: http://www.antibiotic.ru/iacmac/ru/docs/eucast/eucast-expert-rules-intrinsic-resistance-and-exceptionalphenotypes-3.1-rus.pdf (cited 20.04.2020). (in Russian).

29. Hecht D.W. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis. 2004 Jul 1; 39(1): 92–7. doi: 10.1086/421558.

30. Kirchner M., Mafura M., Hunt T., Card R., Anjum M.F. Antibiotic resistance gene profiling of faecal and oral anaerobes collected during an antibiotic challenge trial. Anaerobe. 2013; 23: 20–2. doi: 10.1016/j.anaerobe.2013.07.011.

31. Treviño M., Areses P., Peñalver M.D., Cortizo S., Pardo F., del Molino M.L., García-Riestra C., Hernández M., Llovo J., Regueiro B.J. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe. 2012 Feb; 18(1): 37–43. doi: 10.1016/j.anaerobe.2011.12.022.

32. Aldridge K.E., Ashcraft D., O'Brien M., Sanders C.V. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother. 2003 Jan; 47(1): 148–53. doi: 10.1128/aac.47.1.148-153.2003.

33. Könönen E., Wade W.G. Actinomyces and related organisms in human infections. Clin Microbiol Rev. 2015 Apr; 28(2): 419–42. doi: 10.1128/CMR.00100-14.

34. Marchand-Austin A., Rawte P., Toye B., Jamieson F.B., Farrell D.J., Patel S.N. Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. Anaerobe. 2014; 28: 120–5. doi: 10.1016/j.anaerobe.2014.05.015.

35. Grigorievskaya Z.V., Petukhova I.N., Bagirova N.S., Shilnikova I.I., Tereshchenko I.V., Grigorievsky E.D., Dmitrieva N.V. Nasocomial infectoions in cancer patients: problem of gram-negative bacterial resistance. Siberian Journal of Oncology. 2017; 16(1): 91–97. (in Russian). doi: 10.21294/1814-4861-2017-16-1-91-97.

36. Goldstein E., Citron D. Resistance Trends in Antimicrobial susceptibility of Anaerobic Bacteria, Part II. Clin Microbiol. Newsletter. 2011; 33(1): 1–8. doi: 10.1016/j.clinmicnews.2010.12.001.